ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO579

Palmitoylation of Polycystin 1 Occurs in the Carboxylterminus and May Regulate Polycystin 1 Localization and Expression Levels

Session Information

Category: Genetic Diseases of the Kidney

  • 801 Cystic Kidney Diseases

Authors

  • Roy, Kasturi, Yale School of Medicine, New Haven, Connecticut, United States
  • Stavola, Lindsey K., Yale School of Medicine, New Haven, Connecticut, United States
  • Caplan, Michael J., Yale School of Medicine, New Haven, Connecticut, United States
  • Marin, Ethan P., Yale School of Medicine, New Haven, Connecticut, United States
Background

Polycystin 1 (PC1) is a polytopic membrane protein that localizes to primary cilia. Genetic mutations that lead to reduced PC1 expression levels and/or trafficking to cilia cause cystic disease of the kidney and/or liver. Such mutations may occur in the PC1 gene (Pkd1), or in genes encoding endoplasmic reticuluum proteins involved in the maturation and trafficking of PC1. Cysteine palmitoylation is the post-translational attachment of the 16-carbon lipid palmitic acid to a cysteine sidechain, and is known the affect trafficking and stability of numerous proteins.

Methods

Palmitoylation of PC1 was assessed using a variety of biochemical approaches including incorporation of a clickable palmitate analog as well as acyl exchange methods. Effects of palmitoylation were gauged using chemical inhibitors of palmitoylation and depalmitoylation, coupled with immunofluorescence to assess PC1 localization and semi-quantitative Western blotting to assess PC1 expression levels.

Results

PC1 is palmitoylated on at least one cysteine in the ~140kDa carboxylterminal domain. Experiments using inhibitors of enzymatic palmitoylation and de-palmitoylation suggest that the modification facilitates trafficking of PC1 from the plasma membrane into the cilia membrane. Pharmacological inhibition of palmitoylation or depalmitoylation also alters PC1 expression levels in reciprocal directions

Conclusion

Collectively, these data identify palmitoylation as a novel post-translational modification on PC1 which may affect its trafficking and stability. Both factors are relevant to the development of cystic kidney and liver disease. Consequently, a more detailed understanding of the palmitoylation of PC1 may identify targets to pharmacologically manipulate its expression level and localization, and potentially reverse the effects of disease-causing mutations.

Funding

  • Private Foundation Support